CN104918953A - 抗霉浆菌的亚单位疫苗 - Google Patents

抗霉浆菌的亚单位疫苗 Download PDF

Info

Publication number
CN104918953A
CN104918953A CN201380066435.XA CN201380066435A CN104918953A CN 104918953 A CN104918953 A CN 104918953A CN 201380066435 A CN201380066435 A CN 201380066435A CN 104918953 A CN104918953 A CN 104918953A
Authority
CN
China
Prior art keywords
seq
vaccine
active component
protein
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201380066435.XA
Other languages
English (en)
Other versions
CN104918953B (zh
Inventor
林俊宏
王志鹏
谢明伟
陈正文
方健宇
刘学陶
杨平政
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agricultural Technology Research Institute
Original Assignee
Agricultural Technology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agricultural Technology Research Institute filed Critical Agricultural Technology Research Institute
Publication of CN104918953A publication Critical patent/CN104918953A/zh
Application granted granted Critical
Publication of CN104918953B publication Critical patent/CN104918953B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供抗霉浆菌的亚单位疫苗，特别是合适作为抗霉浆菌的亚单位疫苗的活性成分的蛋白质及以其制得的疫苗。所述蛋白质经实验证实可引发足够强度的免疫反应而避免猪只感染霉浆菌。所述疫苗可含有一种前述的蛋白质作为活性成分，或含有两种以上所述的蛋白质而形成鸡尾酒疫苗的形式。本发明的疫苗不仅较惯用疫苗更具安全性，同时具有相当、甚至是更优异的免疫效果。

Description

PCT国内申请，说明书已公开。

Claims (1)

  1. PCT国内申请，权利要求书已公开。
CN201380066435.XA 2013-02-05 2013-02-05 抗霉浆菌的亚单位疫苗 Active CN104918953B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/071379 WO2014121433A1 (zh) 2013-02-05 2013-02-05 抗霉浆菌的亚单位疫苗

Publications (2)

Publication Number Publication Date
CN104918953A true CN104918953A (zh) 2015-09-16
CN104918953B CN104918953B (zh) 2019-04-02

Family

ID=51299148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380066435.XA Active CN104918953B (zh) 2013-02-05 2013-02-05 抗霉浆菌的亚单位疫苗

Country Status (14)

Country Link
US (7) US9561267B2 (zh)
EP (3) EP2955192B1 (zh)
JP (1) JP6113306B2 (zh)
KR (7) KR101764750B1 (zh)
CN (1) CN104918953B (zh)
BR (1) BR112015018444A2 (zh)
DK (1) DK2955192T3 (zh)
ES (1) ES2812552T3 (zh)
MX (2) MX370715B (zh)
PH (1) PH12015501716A1 (zh)
RU (1) RU2636459C2 (zh)
TW (1) TWI609878B (zh)
UA (2) UA116431C2 (zh)
WO (1) WO2014121433A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026538A (zh) * 2015-12-28 2018-05-11 财团法人农业科技研究院 猪圆环病毒2型的外鞘蛋白质的制备方法及含该外鞘蛋白质的医药组合物
CN110891597A (zh) * 2017-11-01 2020-03-17 财团法人农业科技研究院 防治家禽滑膜霉浆菌感染的组合物

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368864B (es) * 2013-11-21 2019-10-18 Agricultural Tech Res Inst Composicion para prevenir infeccion por mycoplasma spp.
AU2015287993B2 (en) * 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
CN106139137A (zh) * 2015-03-30 2016-11-23 普莱柯生物工程股份有限公司 一种疫苗组合物及其应用
WO2017011919A1 (en) * 2015-07-22 2017-01-26 University Of Saskatchewan Mycoplasma vaccines and uses thereof
TWI606839B (zh) * 2016-08-09 2017-12-01 財團法人農業科技研究院 防治豬鼻黴漿菌感染之組合物及生產該組合物的方法
EP3778626A1 (en) * 2016-08-09 2021-02-17 Agricultural Technology Research Institute Composition for preventing and treating mycoplasma hyorhinis infection, and method for producing said composition
RU2737971C1 (ru) * 2020-05-22 2020-12-07 Эгрикалчурал Текнолоджи Рисерч Инститьют Композиция для профилактики и лечения инфекции mycoplasma hyorhinis и способ получения указанной композиции

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359919A2 (en) * 1988-06-29 1990-03-28 Ml Technology Ventures, L.P. Recombinant mycoplasma hyopneumoniae antigen and uses therefor
CN101217974A (zh) * 2005-07-07 2008-07-09 伯尔尼大学 支原体亚单位疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0571648A1 (en) * 1992-05-26 1993-12-01 Chung-Nan Weng Vaccine protecting against mycoplasmal pneumonia
EP0603406B1 (en) * 1992-05-29 2001-09-19 Nippon Zeon Co., Ltd. Fowl mycoplasma antigen, gene thereof, recombinant vector containing said gene, and vaccine prepared by utilizing the same
DE19816334A1 (de) 1998-04-11 1999-10-14 Krupp Uhde Gmbh Elektrolyseapparat zur Herstellung von Halogengasen
AU6128900A (en) 1999-09-29 2001-04-05 Pfizer Products Inc. Nucleic acids and proteins of the mycoplasma hyopneumoniae mph3 gene and uses thereof
US6537552B1 (en) 1999-10-19 2003-03-25 Iowa State University Research Foundation Vaccine adjuvant
CZ305781B6 (cs) * 2001-07-02 2016-03-16 Zoetis Services Llc Výroba vakcíny Mycoplasma hyopneumoniae
WO2005003313A2 (en) * 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
BR0306775A (pt) * 2003-12-23 2005-10-04 Conselho Nacional Cnpq Polinucleotìdeos codificadores de atividades do cromossomo da bactéria mycoplasma hyopneumoniae
TW200951219A (en) 2008-05-06 2009-12-16 Academia Sinica An improved SUMO fusion protein system for effective production of native proteins
EP2398486A4 (en) * 2009-02-20 2012-11-21 Cdg Therapeutics Inc Compositions and methods for preventing and / or treating cancer by pa-card
CN101638435B (zh) * 2009-09-04 2011-11-16 暨南大学 一种蓝藻病毒蛋白n突变体、其修饰衍生物及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359919A2 (en) * 1988-06-29 1990-03-28 Ml Technology Ventures, L.P. Recombinant mycoplasma hyopneumoniae antigen and uses therefor
CN101217974A (zh) * 2005-07-07 2008-07-09 伯尔尼大学 支原体亚单位疫苗

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GENBANK DATABASE: ""Accession NO：YP_115778，pyruvate dehydrogenase (acetyl-transferring) E1 component subunit alpha [Mycoplasma hyopneumoniae]"", 《GENBANK DATABASE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026538A (zh) * 2015-12-28 2018-05-11 财团法人农业科技研究院 猪圆环病毒2型的外鞘蛋白质的制备方法及含该外鞘蛋白质的医药组合物
CN110891597A (zh) * 2017-11-01 2020-03-17 财团法人农业科技研究院 防治家禽滑膜霉浆菌感染的组合物
CN110891597B (zh) * 2017-11-01 2023-09-22 财团法人农业科技研究院 防治家禽滑膜霉浆菌感染的组合物

Also Published As

Publication number Publication date
US9757441B2 (en) 2017-09-12
KR20150107767A (ko) 2015-09-23
KR101831318B1 (ko) 2018-02-22
WO2014121433A1 (zh) 2014-08-14
PH12015501716B1 (en) 2015-11-09
KR20170082656A (ko) 2017-07-14
DK2955192T3 (en) 2020-08-17
KR101758778B1 (ko) 2017-07-18
MX370715B (es) 2019-12-20
MX2015010102A (es) 2016-04-27
US20170182142A1 (en) 2017-06-29
US20150366959A1 (en) 2015-12-24
US20170196959A1 (en) 2017-07-13
UA115348C2 (uk) 2017-10-25
TWI609878B (zh) 2018-01-01
US9750791B2 (en) 2017-09-05
JP2016514086A (ja) 2016-05-19
JP6113306B2 (ja) 2017-04-12
US9730990B2 (en) 2017-08-15
KR101775434B1 (ko) 2017-09-06
US9750790B2 (en) 2017-09-05
RU2636459C2 (ru) 2017-11-23
MX355078B (es) 2018-04-03
KR101773486B1 (ko) 2017-08-31
EP2955192A4 (en) 2016-11-23
RU2015137851A (ru) 2017-03-14
TW201431873A (zh) 2014-08-16
KR101775435B1 (ko) 2017-09-06
BR112015018444A2 (pt) 2018-05-08
US9561267B2 (en) 2017-02-07
KR20170081759A (ko) 2017-07-12
EP3733691A1 (en) 2020-11-04
US20170202942A1 (en) 2017-07-20
US9775893B2 (en) 2017-10-03
PH12015501716A1 (en) 2015-11-09
EP3733690A1 (en) 2020-11-04
ES2812552T3 (es) 2021-03-17
US20170151318A1 (en) 2017-06-01
KR101764750B1 (ko) 2017-08-03
US20170182144A1 (en) 2017-06-29
KR20170082657A (ko) 2017-07-14
US9750792B2 (en) 2017-09-05
EP2955192B1 (en) 2020-07-01
EP2955192A1 (en) 2015-12-16
KR101838160B1 (ko) 2018-03-13
KR20170081760A (ko) 2017-07-12
KR20170081758A (ko) 2017-07-12
UA116431C2 (uk) 2018-03-12
US20170182143A1 (en) 2017-06-29
CN104918953B (zh) 2019-04-02
KR20170081757A (ko) 2017-07-12

Similar Documents

Publication Publication Date Title
CN104918953A (zh) 抗霉浆菌的亚单位疫苗
Hodak et al. Secretion signal of the filamentous haemagglutinin, a model two‐partner secretion substrate
McDaniel et al. Comparison of the PspA sequence from Streptococcus pneumoniae EF5668 to the previously identified PspA sequence from strain Rx1 and ability of PspA from EF5668 to elicit protection against pneumococci of different capsular types
TWI615402B (zh) 防治黴漿菌感染的組合物
Hounsome et al. Outer membrane protein A of bovine and ovine isolates of Mannheimia haemolytica is surface exposed and contains host species-specific epitopes
Varghees et al. Cloning and porin activity of the major outer membrane protein P1 from Coxiella burnetii
Masri et al. Specific ligand binding attributable to individual epitopes of gonococcal transferrin binding protein A
Najafabadi et al. Designing of a chimeric protein contains StxB, intimin and EscC against toxicity and adherence of enterohemorrhagic Escherichia coli O157: H7 and evaluation of serum antibody titers against it
Kumar et al. Structural features of a highly conserved Omp16 protein of Pasteurella multocida strains and comparison with related peptidoglycan-associated lipoproteins (PAL)
Singh et al. Molecular characterization and computational analysis of the major outer membrane protein (ompH) gene of Pasteurella multocida P52
Mohanty et al. Immunogenicity of recombinant outer membrane protein (OmpW) of Pasteurella multocida serogroup B: 2 in mouse model
JP7230130B2 (ja) マイコプラズマ・ヒオリニス感染を予防治療する組成物及びその活性成分を生産するための発現ベクター及び方法
US20190111122A1 (en) Slam polynucleotides and polypeptides and uses thereof
RU2695679C1 (ru) Субъединичная вакцина против mycoplasma spp.
Huangfu et al. Soluble overexpression and purification of infectious bursal disease virus capsid protein VP2 in Escherichia coli and its nanometer structure observation
WO2004101795A1 (en) Variable proteins of mycoplasma mycoides, vaccines and process thereof
Panangala et al. Organization and sequence of four flagellin‐encoding genes of Edwardsiella ictaluri
Wijaya et al. In Silico Cloning and Analysis of Divalent Subunit OMP31-SOCc Proteins As A Prophylaxis Vaccine Against Brucella melitensis Infection
Sanmukh et al. Unique features of Plasmids among different Citrobacter species
Singh et al. Molekularna karakterizacija i računalna analiza gena ompH za glavni protein stanične stijenke bakterije Pasteurella multocida P52.
Cloward Identification and characterization of a Mycoplasma pneumoniae J-domain co-chaperone required for terminal organelle maturation
Rashmi Singh et al. Molecular characterization and computational analysis of the major outer membrane protein (ompH) gene of Pasteurella multocida P52.

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant